Compare PCRX & VREX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | VREX |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 580.6M |
| IPO Year | 2010 | 2016 |
| Metric | PCRX | VREX |
|---|---|---|
| Price | $22.91 | $10.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $37.20 | $16.67 |
| AVG Volume (30 Days) | ★ 677.8K | 251.5K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.16 | 0.05 |
| Revenue | $541,533,000.00 | ★ $811,000,000.00 |
| Revenue This Year | $7.10 | $5.35 |
| Revenue Next Year | $9.15 | $3.88 |
| P/E Ratio | ★ $145.31 | $206.80 |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $6.76 |
| 52 Week High | $27.99 | $14.57 |
| Indicator | PCRX | VREX |
|---|---|---|
| Relative Strength Index (RSI) | 51.82 | 30.18 |
| Support Level | $22.57 | $9.81 |
| Resistance Level | $23.91 | $12.61 |
| Average True Range (ATR) | 0.93 | 0.39 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 59.86 | 14.63 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Varex Imaging Corp Designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, detectors, ionization chambers, high-voltage connectors, software, collimators, generators, exposure control devices, and heat exchangers.. The company operates through two segments: Medical, the key revenue driver, providing X-ray imaging components and accessories for healthcare applications, and Industrial, which provides Linatron X-ray accelerators, X-ray tubes, flat panel detectors, high-voltage connectors, and coolers for non-medical use. Geographically, it generates the majority of its revenue from Europe, the Middle East, and Africa (EMEA), with the rest coming from the Americas and Asia Pacific.